301
Participants
Start Date
February 17, 2022
Primary Completion Date
July 30, 2023
Study Completion Date
August 7, 2023
HSK16149 40mg BID
HSK16149 40mg , orally twice a day, treatment period; 52-weeks fixed dose.
Peking University First Hospital, Beijing
The First Affiliated Hospital of Anhui Medical University, Hefei
The Second Affiliated Hospital of Anhui Medical University, Hefei
Beijing Pinggu District Hospital, Beijing
Emergency General Hospital, Beijing
The Three Gorges Hospital Affiliated to Chongqing Medical University, Chongqing
The First Hospital of Lanzhou University, Lanzhou
Zhujiang Hospital of Southern Medical University, Guangzhou
Cangzhou People's Hospital, Cangzhou
The Third Hospital of Hebei Medical University, Shijiangzhuang
Kaifeng Hospital of Traditional Chinese Medicine, Kaifeng
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Nanyang First People's Hospital, Nanyang
Wuhan Central Hospital, Wuhan
Nanjing First People's Hospital, Nanjing
Pingxiang People's Hospital, Pingxiang
The First Hospital of Jilin University, Changchun
Baotou Central Hospital, Baotou
Jinan Central Hospital, Jinan
The First Affiliated Hospital of Xi'an Medical University, Xi’an
Yuncheng Central Hospital, Yuncheng
The Second People's Hospital of Yibin, Yibin
Zhejiang Provincial People's Hospital, Hangzhou
Taizhou First People's Hospital, Taizhou
Haisco Pharmaceutical Group Co., Ltd.
INDUSTRY